PBA
SYRE icon

Paradigm Biocapital Advisors’s Spyre Therapeutics SYRE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.7M Buy
1,957,266
+490,000
+33% +$18.5M 2.02% 16
2025
Q4 		$48.1M Hold
1,467,266
– – 1.23% 20
2025
Q3 		$24.6M Sell
1,467,266
-403,179
-22% -$6.57M 0.7% 31
2025
Q2 		$28M Sell
1,870,445
-256,760
-12% -$3.8M 1.2% 23
2025
Q1 		$34.3M Buy
2,127,205
+600,000
+39% +$12.5M 1.57% 18
2024
Q4 		$35.6M Buy
1,527,205
+259,624
+20% +$7.61M 1.24% 20
2024
Q3 		$37.3M Buy
+1,267,581
New +$35.3M 1.26% 26

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Paradigm Biocapital Advisors's SYRE Position: Q1 2026 in Review

Paradigm Biocapital Advisors increased its Spyre Therapeutics (SYRE) stake by 33% in Q1 2026, buying an estimated $18.5M and bringing the position to 1,957,266 shares worth $98.7M. The position accounts for 2.02% of the portfolio, ranked #16.

Paradigm Biocapital Advisors first reported a position in SYRE in Q3 2024 and has held it in 7 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Paradigm Biocapital Advisors held 1,957,266 shares of Spyre Therapeutics worth $98.7M as of Q1 2026.
  • Paradigm Biocapital Advisors bought 490,000 Spyre Therapeutics shares in Q1 2026, an estimated $18.5M.
  • Spyre Therapeutics made up 2.02% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #16 holding.
  • Paradigm Biocapital Advisors first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.